allogeneic mesothelin targeting TRuC-T cell therapy / Adaptimmune - LARVOL DELTA

TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at the American Association of Cancer Research Annual Meeting 2022 (GlobeNewswire) - "TCR2 Therapeutics Inc...today announced it will present a poster at the American Association of Cancer Research (AACR) Annual Meeting 2022 featuring new preclinical data on an allogeneic (off-the-shelf) TRuC-T cells, taking place on April 8-13, 2022 in New Orleans, Louisiana. In preclinical studies, this allogeneic product candidate without an enhancement demonstrated improved anti-tumor efficacy associated with enhanced persistence and increased antigen sensitivity in vivo compared to donor-matched autologous TRuC-T cells targeting mesothelin."

Preclinical • Oncology